Obesity in Co. Kildare: Causes, Risks & Specialist Treatment

← Back to Blog

Obesity is one of the most significant and most misunderstood health challenges facing people in Co. Kildare today. It is not a failure of willpower. It is a chronic, progressive medical condition driven by complex hormonal, genetic, and metabolic factors — and it is highly treatable when managed by a specialist with access to the right tools.

How Common is Obesity in Co. Kildare?

Ireland has one of the highest rates of overweight and obesity in Europe. According to data from the Healthy Ireland Survey and the Irish College of General Practitioners, approximately 60% of Irish adults are either overweight or living with obesity, with around 1 in 4 meeting the clinical definition of obesity (BMI ≥30 kg/m²).

Co. Kildare — one of Ireland's fastest-growing counties, with a population of over 240,000 — reflects this national pattern. Many Kildare residents are working professionals commuting to Dublin, families under time pressure, and individuals whose environment makes healthy food choices and regular exercise structurally difficult. These are not character failures; they are circumstances that directly influence body weight through well-understood biological pathways.

Understanding Obesity as a Medical Disease

The World Health Organisation, the European Association for the Study of Obesity (EASO), and all major Irish and UK medical bodies now classify obesity as a chronic, relapsing, progressive disease — not a lifestyle choice. This is a critical distinction, because it shapes how the condition should be treated.

When a person gains excess body fat, the body's hormonal set-point changes. Appetite-regulating hormones — including leptin (the satiety signal), ghrelin (the hunger signal), and GLP-1 (the gut hormone that slows gastric emptying and reduces appetite) — become dysregulated. The body actively defends a higher body weight and resists weight loss through biological mechanisms, not through lack of motivation.

This is why standard dietary advice and commercial slimming programmes achieve modest long-term results for most people with clinically significant obesity: they do not address the underlying hormonal drivers of weight regain.

Medical Causes of Obesity That Must Be Excluded

Before commencing weight management treatment, a specialist will evaluate whether an underlying medical condition is contributing to weight gain. These are frequently missed in primary care and include:

• Hypothyroidism — an underactive thyroid gland reduces basal metabolic rate and causes weight gain, fatigue, constipation, and cold intolerance. TSH alone is insufficient to exclude subclinical hypothyroidism in all cases.
• Polycystic Ovary Syndrome (PCOS) — affects up to 10% of women of reproductive age and causes insulin resistance, androgen excess, and weight gain, particularly around the abdomen.
• Insulin resistance and pre-diabetes — elevated fasting insulin promotes fat storage, particularly visceral adiposity, and creates a cycle of hunger and weight gain that does not respond well to caloric restriction alone.
• Cushing's syndrome — excess cortisol causes central obesity, facial rounding, hypertension, and muscle weakness. Rare but important to exclude in the right clinical context.
• Medication-induced weight gain — certain antidepressants (mirtazapine, olanzapine), corticosteroids, insulin, beta-blockers, anticonvulsants, and contraceptives can cause significant weight gain as a side effect.
• Sleep apnoea — disrupted sleep architecture alters leptin and ghrelin levels, independently promoting weight gain. Obesity and sleep apnoea are also mutually reinforcing.

Health Risks of Obesity in Co. Kildare Patients

Excess body weight is not simply a cosmetic concern. It is causally linked to over 200 distinct medical conditions, including:

• Type 2 diabetes — visceral fat causes insulin resistance; obesity raises the risk of Type 2 diabetes by up to 80-fold compared with a healthy weight
• Cardiovascular disease — hypertension, dyslipidaemia (high LDL, low HDL), and atherosclerosis are all significantly more prevalent in people with obesity
• Non-alcoholic fatty liver disease (NAFLD) — now called metabolic-associated steatotic liver disease (MASLD), affecting up to 25% of people with obesity and potentially progressing to cirrhosis
• Obstructive sleep apnoea — more than 70% of patients with moderate-to-severe sleep apnoea have obesity
• Osteoarthritis — excess mechanical load on weight-bearing joints, particularly knees and hips
• Certain cancers — obesity increases the risk of at least 13 cancer types, including colorectal, oesophageal, breast (post-menopausal), and endometrial cancers
• Mental health — depression, anxiety, and poor self-esteem are significantly more prevalent in people with obesity, and bidirectionally related

Specialist Obesity Assessment at Naas Clinic

Dr Syed Kashif Hussain Kazmi, Consultant Endocrinologist (Cambridge-trained, FRCPI, FRCP London, IMC: 213626), leads the obesity medicine service at Naas Cardiology & Endocrinology Clinic. Dr Kazmi's endocrinology background means he is ideally placed to identify and treat the hormonal and metabolic causes of obesity that general weight-loss services are not equipped to address.

A comprehensive first consultation includes:

• Full medical and weight history — including previous weight loss attempts, medications, family history, and comorbidities
• Physical examination — BMI, waist circumference, blood pressure, and assessment for signs of secondary causes
• Targeted blood tests — thyroid function, fasting glucose, HbA1c, fasting insulin, lipid profile, liver function, full blood count, and hormonal panels where indicated
• Review of current medications and identification of any agents contributing to weight gain
• Individualised treatment plan — incorporating dietary strategy, physical activity guidance, behavioural support, and pharmacological options where appropriate

Treatment Options for Obesity

Effective obesity management is multimodal. There is no single intervention that works for every patient. Dr Kazmi develops a personalised treatment plan based on the individual's medical profile, preferences, and goals.

Dietary and lifestyle optimisation

Evidence-based nutritional approaches — including lower-carbohydrate diets, time-restricted eating, and Mediterranean dietary patterns — are discussed in detail at consultation. These are not generic "eat less" instructions; they are strategies tailored to the patient's metabolic phenotype, work schedule, and food preferences.

Management of underlying conditions

Where hypothyroidism, insulin resistance, PCOS, or other contributing conditions are identified, treating these directly can significantly improve weight outcomes — and must be addressed before pharmacological weight loss treatment is initiated.

GLP-1 Receptor Agonist Therapy

The most significant advance in obesity medicine in a generation has been the development of GLP-1 (glucagon-like peptide-1) receptor agonists. These medications work by mimicking the body's natural gut hormones to reduce appetite, slow gastric emptying, and improve insulin sensitivity. They are not "injections to make you thin" — they are precision medical treatments that correct the hormonal dysregulation underlying obesity.

Dr Kazmi prescribes the following GLP-1 based therapies for eligible patients in Kildare:

• Semaglutide (Wegovy) — approved in Ireland for chronic weight management (BMI ≥30, or ≥27 with comorbidity). Clinical trials (STEP programme) demonstrated average weight loss of 14.9% of body weight over 68 weeks. Administered as a once-weekly subcutaneous injection with gradual dose escalation over 16–20 weeks.
• Tirzepatide (Mounjaro) — a dual GLP-1/GIP receptor agonist. Trials (SURMOUNT programme) demonstrated average weight loss of 20.9% at the highest dose — the greatest efficacy of any approved weight management medication to date. Also a once-weekly subcutaneous injection.
• Semaglutide (Ozempic) — the lower-dose version of semaglutide, licensed for Type 2 diabetes management but also associated with clinically meaningful weight loss and significant cardiovascular risk reduction (SUSTAIN-6 and SELECT trials).

Bariatric surgery referral

For patients with BMI ≥40 kg/m², or ≥35 with significant comorbidities, who have not achieved adequate results with medical management, bariatric surgery referral may be appropriate. Dr Kazmi can facilitate referral to accredited bariatric surgery programmes and will provide pre-operative endocrinological optimisation where required.

GLP-1 Treatment in Co. Kildare: What to Expect

Many patients attending from Naas, Newbridge, Athy, Celbridge, Maynooth, Clane, and across Kildare ask about the practical aspects of starting GLP-1 therapy. Here is a typical pathway:

1. Initial consultation (45–60 minutes) — full history, examination, and baseline bloods. A treatment plan is formulated and, if appropriate, GLP-1 therapy is discussed.
2. Starting dose — semaglutide and tirzepatide are both started at the lowest dose to minimise gastrointestinal side effects, with dose escalation every 4 weeks.
3. Follow-up — typically at 4–8 week intervals during dose escalation, then every 3 months once on a stable dose.
4. Expected outcomes — most patients notice reduced appetite within the first 1–2 weeks. Meaningful weight loss (≥5%) is typically seen within 12 weeks. Maximum weight loss is usually achieved between 12 and 18 months.
5. Long-term — GLP-1 therapy is most effective when maintained long-term. Discontinuation is associated with weight regain, reflecting the ongoing hormonal nature of the condition.

Towns Served Across Co. Kildare

The obesity medicine service at Naas Clinic accepts patients from across Co. Kildare and surrounding counties, including:

Naas, Newbridge, Kildare Town, Athy, Celbridge, Leixlip, Maynooth, Clane, Sallins, Kilcullen, Monasterevin, Rathangan, and Kilcock. Patients from Co. Wicklow, Co. Laois, Co. Carlow, and South Co. Dublin also attend regularly.

The clinic is located at Suite 5, Vista Primary Care Clinic, Ballymore Road, Naas — easily accessible from the M7 motorway corridor, with free on-site parking. Appointments are available on Sundays, 9am–5pm, to accommodate working patients and families.

Frequently Asked Questions